4-[4-(乙氧基羰基)哌啶]苯甲酸 | 179487-86-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-[4-(乙氧基羰基)哌啶]苯甲酸
• 英文名称: 1-(4-carboxy-phenyl)-piperidine-4-carboxylic acid ethyl ester
• 英文别名: Ethyl 1-(4-carboxy)phenyl-4-piperidinecarboxylate；4-[4-(Ethoxycarbonyl)piperidin-1-yl]benzoic acid；4-(4-ethoxycarbonylpiperidin-1-yl)benzoic acid
• CAS: 179487-86-6
• 化学式: C₁₅H₁₉NO₄
• 分子量: 277.32
• InChiKey: OSFJSOISEOYJTA-UHFFFAOYSA-N

物化性质

• 沸点：
  448.7±40.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[4-(乙氧基羰基)哌啶]苯甲酸 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.17h， 生成 3-bromo-4-[4-(ethoxycarbonyl)piperidin-1-yl]benzoic acid
  参考文献：
  名称：

  2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF

  摘要：

  公开号：

  EP1466912B1
• 作为产物：
  描述：

  4-氟苯甲酸苄酯 在 4-二甲氨基吡啶 、 palladium 10% on activated carbon 氢气 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 120.0 ℃ 、101.33 kPa 条件下， 反应 3.5h， 生成 4-[4-(乙氧基羰基)哌啶]苯甲酸
  参考文献：
  名称：

  Diacylglycerol Acyltransferase Inhibitors

  摘要：

  本文提供了化合物的公式（I）：其中R1为苯基，R2为氢、卤素或低碳烷基，X为碳或氮，R3为异喹啉基、氨基或含有4至6个成员的杂环烷基环，并且其药学上可接受的盐，这些化合物作为DGAT抑制剂具有活性，因此可用于治疗与三酸甘油酯异常代谢相关的疾病，例如肥胖症、2型糖尿病和代谢综合征。

  公开号：

  US20100113782A1

文献信息

• 2-Acylaminothiazole derivative or salt thereof
  申请人：Sugasawa Keizo

  公开号：US20050153977A1

  公开（公告）日：2005-07-14

  A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.

  一种2-酰胺基噻唑衍生物或其药学上可接受的盐，具有优异的促进人类c-mpl-Ba / F3细胞增殖和增加血小板活性的作用，基于促进巨核细胞集落形成的效果。一种化合物或其药学上可接受的盐，用于治疗血小板减少症。
• 2-acylaminothiazole derivative or salt thereof
  申请人：Astellas Pharma, Inc.

  公开号：US08338429B2

  公开（公告）日：2012-12-25

  A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.

  一种2-酰胺基噻唑衍生物或其药学上可接受的盐，具有促进人类c-mpl-Ba/F3细胞增殖和增加血小板的活性，基于促进巨核细胞集落形成的作用。一种化合物或其药学上可接受的盐，可用于治疗血小板减少症。
• Diacylglycerol acyltransferase inhibitors
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：US08324385B2

  公开（公告）日：2012-12-04

  Provided herein are compounds of the formula (I): were RI is phenyl, R2 is hydrogen, halogen or lower alkyl, X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a -4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of trigliceride. such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了式(I)的化合物：其中RI是苯基，R2是氢，卤素或低碳基，X是碳或氮，R3是异喹啉，-氨基或-4-至6-成员杂环烷基环，以及其药学上可接受的盐。这些化合物作为DGAT抑制剂具有活性，因此可用于治疗与三酰甘油异常代谢有关的疾病，例如肥胖症、2型糖尿病和代谢综合征。
• Development of second generation EP2 antagonists with high selectivity
  作者：Thota Ganesh、Jianxiong Jiang、Ray Dingledine

  DOI：10.1016/j.ejmech.2014.05.076

  日期：2014.7

  EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors. (C) 2014 Elsevier Masson SAS. All rights reserved.
• DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：EP2350311B1

  公开（公告）日：2013-12-25